𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales

✍ Scribed by Brown, Ruth E.; Stern, Sean; Dhanasiri, Sujith; Schey, Steve

Book ID
121636720
Publisher
Springer
Year
2012
Tongue
French
Weight
255 KB
Volume
14
Category
Article
ISSN
1618-7598

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Combined pegylated liposomal doxorubicin
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy
✍ Pieter Sonneveld; Roman Hajek; Arnon Nagler; Andrew Spencer; Joan BladΓ©; Tadeusz πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 137 KB

## Abstract ## BACKGROUND Recently, the authors reported improved time to disease progression (TTP) with a combination of pegylated liposomal doxorubicin (PLD) and bortezomib compared with bortezomib alone in a phase 3 randomized trial in patients with recurrent/refractory multiple myeloma (MM). I